{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:11:49Z","timestamp":1794438709335,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004621","name":"Kerman University of Medical Sciences","doi-asserted-by":"publisher","award":["403000093"],"award-info":[{"award-number":["403000093"]}],"id":[{"id":"10.13039\/501100004621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15372-6","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T03:53:53Z","timestamp":1764129233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Niosomal mefloquine and cisplatin in breast cancer: comparative effects on apoptosis and angiogenesis via in vitro and in silico analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Zohreh","family":"Salari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezo","family":"Riahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Molaakbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Salarkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Reza","family":"Keyhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Sohbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin Raeisi","family":"Estabragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"1","key":"15372_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"Cancer J Clin"},{"key":"15372_CR2","doi-asserted-by":"crossref","unstructured":"Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19(6):608\u201315.","DOI":"10.1634\/theoncologist.2014-0002"},{"key":"15372_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293:247\u201369.","journal-title":"Arch Gynecol Obstet"},{"issue":"9","key":"15372_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.693","volume":"5","author":"S Wang","year":"2024","unstructured":"Wang S, Guo S, Guo J, Du Q, Wu C, Wu Y, et al. Cell death pathways: molecular mechanisms and therapeutic targets for cancer. MedComm. 2024;5(9):e693.","journal-title":"MedComm"},{"key":"15372_CR5","doi-asserted-by":"crossref","unstructured":"Wang S, Chen X, Zhang X, Wen K, Chen X, Gu J, et al. Pro-apoptotic gene BAX is a pan-cancer predictive biomarker for prognosis and immunotherapy efficacy. Aging. 2024;16(14):11289\u2013317.","DOI":"10.18632\/aging.206003"},{"key":"15372_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103485","volume":"80","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Liu X, Wei Q, Xiong S, Luo W, Zhou Y, et al. Apoptotic breast cancer cells after chemotherapy induce pro-tumour extracellular vesicles via LAP-competent macrophages. Redox Biol. 2025;80:103485.","journal-title":"Redox Biol"},{"key":"15372_CR7","doi-asserted-by":"crossref","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.","DOI":"10.1186\/s12943-023-01805-y"},{"issue":"1","key":"15372_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"A-M Florea","year":"2011","unstructured":"Florea A-M, B\u00fcsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3(1):1351\u201371.","journal-title":"Cancers"},{"issue":"75","key":"15372_CR9","doi-asserted-by":"publisher","first-page":"34038","DOI":"10.18632\/oncotarget.25954","volume":"9","author":"R Ramer","year":"2018","unstructured":"Ramer R, Schmied T, Wagner C, Haustein M, Hinz B. The antiangiogenic action of cisplatin on endothelial cells is mediated through the release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Oncotarget. 2018;9(75):34038\u201355.","journal-title":"Oncotarget"},{"key":"15372_CR10","doi-asserted-by":"crossref","unstructured":"Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 2020;11:343.","DOI":"10.3389\/fphar.2020.00343"},{"key":"15372_CR11","doi-asserted-by":"crossref","unstructured":"Ho AN, Kiesel VA, Gates CE, Brosnan BH, Connelly SP, Glenny EM, et al. Exogenous metabolic modulators improve response to carboplatin in Triple-Negative breast cancer. Cells. 2024;13(10):806.","DOI":"10.3390\/cells13100806"},{"key":"15372_CR12","doi-asserted-by":"publisher","unstructured":"Berg AL, Rowson-Hodel A, Wheeler MR, Hu M, Free S, Carraway KL III. Engaging the lysosome and lysosome-dependent cell death in cancer. In: Exon Publications; 2022;195\u2013230. https:\/\/doi.org\/10.36255\/exon-publications-breast-cancer-lysosome.","DOI":"10.36255\/exon-publications-breast-cancer-lysosome"},{"issue":"6","key":"15372_CR13","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/infdis\/171.6.1569","volume":"171","author":"WR Weiss","year":"1995","unstructured":"Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis. 1995;171(6):1569\u201375.","journal-title":"J Infect Dis"},{"key":"15372_CR14","volume-title":"Manson\u2019s Tropical Diseases E-Book","author":"J Farrar","year":"2023","unstructured":"Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ, et al. Manson\u2019s Tropical Diseases E-Book. Elsevier health sciences; 2023. https:\/\/www.sciencedirect.com\/book\/9780702079597\/mansons-tropical-diseases."},{"key":"15372_CR15","doi-asserted-by":"crossref","unstructured":"Wong W, Bai X-C, Sleebs BE, Triglia T, Brown A, Thompson JK, et al. Mefloquine targets the plasmodium falciparum 80S ribosome to inhibit protein synthesis. Nat Microbiol. 2017;2(6):1\u20139.","DOI":"10.1038\/nmicrobiol.2017.31"},{"key":"15372_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbrc.2021.09.069","volume":"580","author":"B Wan","year":"2021","unstructured":"Wan B, Wu Z, Zhang X, Huang B. Mefloquine as a dual inhibitor of glioblastoma angiogenesis and glioblastoma via disrupting lysosomal function. Biochem Biophys Res Commun. 2021;580:7\u201313.","journal-title":"Biochem Biophys Res Commun"},{"key":"15372_CR17","doi-asserted-by":"publisher","unstructured":"Xiang W, Lam YH, Sng C, Cheong MA, Than H, Hwang WY, et al. Mefloquine effectively targets blast phase chronic myeloid leukemia through inducing oxidative stress and lysosomal disruption. In.: American Society of Hematology Washington, DC; 2016. https:\/\/doi.org\/10.1182\/blood.V128.22.5426.5426.","DOI":"10.1182\/blood.V128.22.5426.5426"},{"key":"15372_CR18","doi-asserted-by":"publisher","unstructured":"Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR. Relation between mitochondrial membrane potential and ROS formation. In: Mitochondrial Bioenergetics: Methods Protocols. 2012;183\u2013205. https:\/\/doi.org\/10.1007\/978-1-61779-382-0_12.","DOI":"10.1007\/978-1-61779-382-0_12"},{"key":"15372_CR19","doi-asserted-by":"crossref","unstructured":"Yan K-H, Yao C-J, Hsiao C-H, Lin K-H, Lin Y-W, Wen Y-C, et al. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling. Oncol Lett. 2013;5(5):1541\u20135.","DOI":"10.3892\/ol.2013.1211"},{"issue":"2","key":"15372_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.bbrc.2016.01.046","volume":"470","author":"Y Liu","year":"2016","unstructured":"Liu Y, Chen S, Xue R, Zhao J, Di M. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K\/Akt\/mTOR signaling pathway. Biochem Biophys Res Commun. 2016;470(2):350\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"15372_CR21","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/cas.13540","volume":"109","author":"X Xu","year":"2018","unstructured":"Xu X, Wang J, Han K, Li S, Xu F, Yang Y. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells. Cancer Sci. 2018;109(4):1220\u20139.","journal-title":"Cancer Sci"},{"key":"15372_CR22","doi-asserted-by":"crossref","unstructured":"Sharma N, Thomas S, Golden EB, Hofman FM, Chen TC, Petasis NA, et al. Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett. 2012;326(2):143\u201354.","DOI":"10.1016\/j.canlet.2012.07.029"},{"issue":"4","key":"15372_CR23","first-page":"836","volume":"14","author":"MAR Estabragh","year":"2024","unstructured":"Estabragh MAR, Behnam B, Torkzadeh-Mahani M, Pardakhty A. Niosome as a drug delivery carrier for sorafenib: preparation, investigation of physicochemical properties, and in vitro effects on HepG2 cell line. Adv Pharm Bull. 2024;14(4):836.","journal-title":"Adv Pharm Bull"},{"issue":"3","key":"15372_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.34172\/apb.2022.058","volume":"12","author":"MAR Estabragh","year":"2021","unstructured":"Estabragh MAR, Pardakhty A, Ahmadzadeh S, Dabiri S, Afshar RM, Abbasi MF. Successful application of alpha lipoic acid niosomal formulation in cerebral ischemic reperfusion injury in rat model. Adv Pharm Bull. 2021;12(3):541.","journal-title":"Adv Pharm Bull"},{"issue":"7","key":"15372_CR25","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1021\/acs.molpharmaceut.7b00352","volume":"14","author":"MA Obeid","year":"2017","unstructured":"Obeid MA, Elburi A, Young LC, Mullen AB, Tate RJ, Ferro VA. Formulation of nonionic surfactant vesicles (NISV) prepared by microfluidics for therapeutic delivery of SiRNA into cancer cells. Mol Pharm. 2017;14(7):2450\u20138.","journal-title":"Mol Pharm"},{"key":"15372_CR26","volume":"4","author":"MA Obeid","year":"2022","unstructured":"Obeid MA, Khadra I, Aljabali AA, Amawi H, Ferro VA. Characterisation of niosome nanoparticles prepared by microfluidic mixing for drug delivery. International Journal of Pharmaceutics: X. 2022;4:100137.","journal-title":"International Journal of Pharmaceutics: X"},{"key":"15372_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.apsusc.2016.02.092","volume":"380","author":"A Ritwiset","year":"2016","unstructured":"Ritwiset A, Krongsuk S, Johns JR. Molecular structure and dynamical properties of niosome bilayers with and without cholesterol incorporation: a molecular dynamics simulation study. Appl Surf Sci. 2016;380:23\u201331.","journal-title":"Appl Surf Sci"},{"key":"15372_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2020.114812","volume":"322","author":"R Pelalak","year":"2021","unstructured":"Pelalak R. Molecular dynamics simulation of novel diamino-functionalized Hollow mesosilica spheres for adsorption of dyes from synthetic wastewater. J Mol Liq. 2021;322:114812.","journal-title":"J Mol Liq"},{"issue":"6","key":"15372_CR29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0731-7085(01)00635-5","volume":"27","author":"AB Rao","year":"2002","unstructured":"Rao AB, Murthy R. A rapid spectrophotometric method for the determination of mefloquine hydrochloride. J Pharm Biomed Anal. 2002;27(6):959\u201365.","journal-title":"J Pharm Biomed Anal"},{"key":"15372_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ctrv.2017.11.003","volume":"62","author":"A Lee","year":"2018","unstructured":"Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110\u201322.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"15372_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4174\/astr.2015.89.1.1","volume":"89","author":"SH Lee","year":"2015","unstructured":"Lee SH, Jeong D, Han YS, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015;89(1):1\u20138.","journal-title":"Ann Surg Treat Res"},{"key":"15372_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031665","author":"P Ferrari","year":"2022","unstructured":"Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031665.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"15372_CR33","first-page":"571","volume":"21","author":"J Mou","year":"2024","unstructured":"Mou J, Li C, Zheng Q, Meng X, Tang H. Research progress in tumor angiogenesis and drug resistance in breast cancer. Cancer Biol Med. 2024;21(7):571\u201385.","journal-title":"Cancer Biol Med"},{"issue":"199","key":"15372_CR34","first-page":"2161","volume":"8","author":"G Mereddy","year":"2018","unstructured":"Mereddy G, Ronayne C. Repurposing antimalarial drug mefloquine for cancer treatment. Transl Med (Sunnyvale). 2018;8(199):2161\u201310251000199.","journal-title":"Transl Med (Sunnyvale)"},{"issue":"9","key":"15372_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.tranon.2019.06.001","volume":"12","author":"H Lam Yi","year":"2019","unstructured":"Lam Yi H, Than H, Sng C, Cheong MA, Chuah C, Xiang W. Lysosome Inhibition by mefloquine preferentially enhances the cytotoxic effects of tyrosine kinase inhibitors in blast phase chronic myeloid leukemia. Transl Oncol. 2019;12(9):1221\u20138.","journal-title":"Transl Oncol"},{"key":"15372_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137241","author":"R Ali","year":"2022","unstructured":"Ali R, Aouida M, Alhaj Sulaiman A, Madhusudan S, Ramotar D. Can cisplatin therapy be improved? Pathways that can be targeted. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23137241.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"15372_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/0113894501294182240401060343","volume":"25","author":"Q Li","year":"2024","unstructured":"Li Q, Chen S, Wang X, Cai J, Huang H, Tang S, et al. Cisplatin-based combination therapy for enhanced cancer treatment. Curr Drug Targets. 2024;25(7):473\u201391.","journal-title":"Curr Drug Targets"},{"key":"15372_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1098429","volume":"13","author":"Z Salari","year":"2023","unstructured":"Salari Z, Khosravi A, Pourkhandani E, Molaakbari E, Salarkia E, Keyhani A, et al. The inhibitory effect of 6-gingerol and cisplatin on ovarian cancer and antitumor activity: in silico, in vitro, and in vivo. Front Oncol. 2023;13:1098429.","journal-title":"Front Oncol"},{"issue":"6","key":"15372_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/app15063189","volume":"15","author":"I-A Vagena","year":"2025","unstructured":"Vagena I-A, Malapani C, Gatou M-A, Lagopati N, Pavlatou EA. Enhancement of EPR effect for passive tumor targeting: current status and future perspectives. Appl Sci. 2025;15(6):3189.","journal-title":"Appl Sci"},{"issue":"8","key":"15372_CR40","doi-asserted-by":"publisher","first-page":"e18710","DOI":"10.1016\/j.heliyon.2023.e18710","volume":"9","author":"T Bashkeran","year":"2023","unstructured":"Bashkeran T, Kamaruddin AH, Ngo TX, Suda K, Umakoshi H, Watanabe N, et al. Niosomes in cancer treatment: a focus on curcumin encapsulation. Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18710.","journal-title":"Heliyon"},{"key":"15372_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.123686","volume":"235","author":"MS Sharafshadeh","year":"2023","unstructured":"Sharafshadeh MS, Tafvizi F, Khodarahmi P, Ehtesham S. Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy. Int J Biol Macromol. 2023;235:123686.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"15372_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-021-00085-9","volume":"12","author":"F Dabbagh Moghaddam","year":"2021","unstructured":"Dabbagh Moghaddam F, Akbarzadeh I, Marzbankia E, Farid M, Khaledi L, Reihani AH, et al. Delivery of melittin-loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti-cancer effect. Cancer Nanotechnol. 2021;12(1):14.","journal-title":"Cancer Nanotechnol"},{"key":"15372_CR43","doi-asserted-by":"publisher","first-page":"860598","DOI":"10.3389\/fphar.2022.860598","volume":"13","author":"A Khosravi","year":"2022","unstructured":"Khosravi A, Sharifi I, Tavakkoli H, Molaakbari E, Bahraminegad S, Salarkia E, et al. Cytotoxicity of amphotericin B and ambisome: in silico and in vivo evaluation employing the chick embryo model. Front Pharmacol. 2022;13:860598.","journal-title":"Front Pharmacol"},{"issue":"1","key":"15372_CR44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13046-020-01724-6","volume":"39","author":"F Mudassar","year":"2020","unstructured":"Mudassar F, Shen H, O\u2019Neill G, Hau E. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J Exp Clin Cancer Res. 2020;39(1):208.","journal-title":"J Exp Clin Cancer Res"},{"key":"15372_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.tiv.2018.12.018","volume":"56","author":"A Khosravi","year":"2019","unstructured":"Khosravi A, Sharifi I, Tavakkoli H, Keyhani AR, Afgar A, Salari Z, et al. Toxico-pathological effects of meglumine antimoniate on human umbilical vein endothelial cells. Toxicol In Vitro. 2019;56:10\u20138.","journal-title":"Toxicol In Vitro"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15372-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:55:53Z","timestamp":1767707753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15372-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15372"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15372-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committees of Afzalipour Hospital, Kerman University of Medical Sciences (Approval ID: IR.KMU.AH.REC.1403.149).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Abbreviations\n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Cisplatin (CIS).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Combination Index (CI).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Dulbecco\u2019s Modified Eagle Medium (DMEM).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Encapsulation Efficiency (EE).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Enzyme-linked immuno_sorbent assay (ELISA).","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Fetal Bovine Serum (FBS).","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Flow Rate (TFR).","order":12,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Flow Rate Ratio (FRR).","order":13,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Inhibitory Concentrations (IC50).","order":14,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Mefloquine (MEF).","order":15,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Niosomal Mefloquine (NMEF).","order":16,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Nuclear Factor kappa B (NF-\u03baB).","order":17,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Optical Density (OD).","order":18,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Phosphate-Buffered Saline (PBS).","order":19,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Polydispersity Index (PDI).","order":20,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- quantitative Real-Time PCR (qPCR).","order":21,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Reactive Oxygen Species (ROS).","order":22,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Selective Index (SI).","order":23,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Triple-Negative Breast Cancer (TNBC).","order":24,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Vascular Endothelial Growth Factor (VEGF).","order":25,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"- Vascular Endothelial Growth Factor Receptor (KDR).","order":26,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}